Cite
HARVARD Citation
Puzanov, I. et al. (n.d.). Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma. Journal for immunotherapy of cancer. p. . [Online].